EUVIMEDEUVIMED entdecken
Crossref

Src Family Kinase Inhibitors Bosutinib and Dasatinib Enhance ATRA-induced Differentiation of NB4 Leukemia Cells

Min-Young Lee, Hee-Jeong Cheong, Seug Yun Yoon, Kyoung Ha Kim, Namsu Lee, Rojin Park, Seong Kyu Park, Jong-Ho Won

Anticancer Research · 2026-07 · 46 (7) · 3831-3844

DOI: 10.21873/anticanres.18244 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, online erschienen am 29.06.2026. Verfasst von Min-Young Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Aniline Compounds, Tretinoin, Dasatinib, Quinolines.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Acute promyelocytic leukemia (APL) has been treated for decades with all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO), which achieve excellent survival but remain limited by induction mortality, ATO-related toxicities, and relapse in some patients. Src family kinases (SFKs) regulate proliferation and survival of myeloid lineage cells, and SFK inhibition has been reported to enhance retinoic acid (RA)-induced differentiation. We investigated whether clinically available SFK inhibitors can augment ATRA-induced differentiation of APL-derived NB4 cells more effectively than the ATRA plus ATO standard regimen. MATERIALS AND METHODS: NB4 cells were treated with PP2, bosutinib, or dasatinib with or without ATRA. Differentiation was assessed by CD11b expression using flow cytometry and by nitroblue tetrazolium reduction. SFK phosphorylation and retinoic acid receptor (RAR) target gene expression were evaluated by immunoblotting. Apoptosis was analyzed to distinguish differentiation from cytotoxic effects. RESULTS:

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aniline CompoundsTretinoinDasatinibQuinolinesCell DifferentiationLeukemia, Promyelocytic, Acutesrc-Family KinasesProtein Kinase InhibitorsNitrilesHumansCell Line, TumorApoptosisArsenic TrioxideCD11b AntigenDrug SynergismPhosphorylationPyrimidinesCell Proliferation

Stichwörter der Autor:innen

Src-family kinasesacute promyelocytic leukemiaall-trans-retinoic acidarsenic trioxidebosutinibdasatinib

Substanzen

bosutinibAniline CompoundsTretinoinDasatinibQuinolinessrc-Family KinasesProtein Kinase InhibitorsNitrilesArsenic TrioxideCD11b Antigen

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea.
  • Institute for Clinical Molecular Biology Research, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea.
  • Department of Laboratory Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea.
  • Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Republic of Korea.
  • Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea; jhwon@schmc.ac.kr.

Zitieren

APA

Lee, M. Y., Cheong, H. J., Yoon, S. Y., Kim, K. H., Lee, N., Park, R., Park, S. K., & Won, J. H. (2026). Src Family Kinase Inhibitors Bosutinib and Dasatinib Enhance ATRA-induced Differentiation of NB4 Leukemia Cells. Anticancer Research, 46(7), 3831-3844. https://doi.org/10.21873/anticanres.18244

Vancouver

Lee MY, Cheong HJ, Yoon SY, Kim KH, Lee N, Park R, et al. Src Family Kinase Inhibitors Bosutinib and Dasatinib Enhance ATRA-induced Differentiation of NB4 Leukemia Cells. Anticancer Research. 2026;46(7):3831-3844. doi:10.21873/anticanres.18244

BibTeX
@article{Lee2026,
  author = {Lee, Min-Young and Cheong, Hee-Jeong and Yoon, Seug Yun and Kim, Kyoung Ha and Lee, Namsu and Park, Rojin and Park, Seong Kyu and Won, Jong-Ho},
  title = {Src Family Kinase Inhibitors Bosutinib and Dasatinib Enhance ATRA-induced Differentiation of NB4 Leukemia Cells},
  journal = {Anticancer Research},
  year = {2026},
  volume = {46},
  number = {7},
  pages = {3831--3844},
  doi = {10.21873/anticanres.18244}
}
Kostenlos starten →